BioRestorative Therapies, Inc. BRTX PHARMA

Q: What is the current share price of BioRestorative Therapies, Inc. (BRTX)?

As of 2026-09-19 21:16 PDT, BioRestorative Therapies, Inc. (BRTX) trades at $2.80 on NasdaqCM. Its 52-week range is $0.14 to $2.96.

Q: What is the market capitalisation of BRTX?

BioRestorative Therapies, Inc. (BRTX) has a market capitalisation of $3.87M on NasdaqCM.

Q: What is the P/E ratio of BRTX?

BRTX trades at a trailing price-to-earnings (P/E) ratio of -0.13. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.15.

Q: Is BRTX a good stock to buy?

This page provides a data-driven analysis of BioRestorative Therapies, Inc. (BRTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.biorestorative.com

Company Profile ↓

$2.80

+86.85% 1Y

Mkt Cap$3.87M

P/E-0.13

P/B1.15

52W High$2.96

52W Low$0.14

Book Value$2.38

EPS (TTM)$-21.20

Company Overview

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 36.1% CAGR over the past five years.

Recent Developments

Dec 2025 Revenue of $359.70K (-10.3% YoY); net profit $-14.24M.
Trailing 12 Months Year-on-year growth — revenue -7.3%.
5-Year Trend Long-term compounding — revenue CAGR 36.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	36.11%
1 Year:	-7.30%

Stock Price Performance

1 Year:	+86.85%
6 Months:	+1,094.21%
3 Months:	+674.25%
1 Month:	+1,273.92%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 94% of range

$0.14 $2.96

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)91.10 · Overbought

Price Performance

1M+1,273.92%

3M+674.25%

6M+1,094.21%

1Y+86.85%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 36.1% over 5 years.

CONS

In a downtrend (50-DMA below 200-DMA).
RSI at 91 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.13

Industry PE

24.83

Forward P/E

-0.27

PEG Ratio

Book Value

$2.38

Price to Book

1.15

P/S

10.57

EV/EBITDA

-0.00

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

36.11%

Profit 5Y

Revenue (YoY)

-7.30%

Earnings (YoY)

Profitability & Returns

ROCE

ROE

ROA

Profit Margin

0.00%

Op Margin

Gross Margin

92.09%

EPS (Latest Qtr)

$-0.12

EPS (TTM)

$-21.20

Balance Sheet & Liquidity

Debt/Equity

0.95

Quick Ratio

2.23

Current Ratio

2.35

Debt

$28.77K

Total Assets

$4.64M

Current Assets

Working Capital

Ownership

Promoter Holding

9.56%

Chg in Prom Hold

FII / Inst Holding

13.90%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$3.87M

Total Revenue (TTM)

$357.87K

EBITDA

$-14.01M

Free Cash Flow

$-9.71M

Operating Cash Flow

$-11.82M

Shares Outstanding

1.38M

Gross Margin

92.09%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	BRTX BioRestorative Therapies, Inc. PHARMA	2.80	-0.13	$3.87M	0.00%	-	-	36.11%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2013	Jun 2013	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.00K	37.00K	26.00K	29.00K	31.00K	38.00K	26.00K	19.00K	15.00K	18.00K	15.00K	8.00K	16.00K	71.10K	29.00K	31.30K	64.50K	30.70K	35.00K	89.10K	233.60K	25.00K	303.30K	11.80K	23.17K
Gross Profit	968	389	115	315	133.57K	93.81K	108.47K	74.12K	45.20K	9.12K	16.08K	5.00K	7.00K	20.00K	16.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	64.50K	30.70K	35.00K	82.61K	215.36K	22.09K	294.57K	1.23K	15.79K
Operating Income	-1.30M	-1.11M	-1.13M	-1.43M	-1.28M	-896.01K	-1.63M	-1.26M	-1.49M	-2.07M	-2.14M	-1.72M	-2.49M	-2.57M	-1.74M	-2.23M	-2.05M	-1.19M	-2.33M	-2.13M	-1.82M	-818.99K	-461.59K	-610.26K	-15.05M	-3.56M	-3.69M	-5.05M	-4.63M	-4.61M	-5.78M	-3.12M	-3.10M	-4.11M	-2.47M	-2.29M	-4.81M	-3.31M	-3.71M	-3.39M
Net Income	-1.57M	-1.25M	-1.30M	-1.67M	-1.33M	-1.10M	-1.76M	-1.42M	-1.62M	-2.49M	-2.26M	-1.83M	-2.79M	-2.75M	-2.05M	-2.51M	-3.51M	-2.93M	-3.88M	-4.16M	-5.06M	-7.55M	2.88M	-836.26K	-15.65M	-4.06M	-4.18M	-4.82M	-4.68M	-4.66M	-7.17M	-5.71M	4.77M	-2.22M	-4.03M	-1.09M	-5.34M	-2.66M	-3.04M	-2.15M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.24	-	-	0.00	-	-	-	-	-	-1.28	-1.28	-1.93	-1.47	0.39	-0.33	-0.50	-0.13	-0.64	-0.30	-0.33	-0.12
R&D Expense	400.44K	372.92K	414.92K	493.74K	293.33K	290.71K	406.86K	452.49K	615.65K	866.04K	608.69K	656.17K	805.85K	610.73K	490.65K	407.13K	372.81K	357.44K	455.01K	441.72K	409.81K	186.33K	261.55K	251.04K	165.25K	160.90K	237.41K	775.34K	1.08M	989.17K	1.23M	902.89K	809.82K	1.06M	1.45M	1.45M	2.65M	2.23M	2.59M	1.93M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	0	15.59K	1.68K	416.00K	628.91K	36.35K	81.00K	111.00K	130.00K	77.00K	46.00K	119.80K	145.80K	401.00K	359.70K
Gross Profit	-	-	0	14.28K	1.47K	202.16K	367.41K	36.25K	81.00K	-	-	-	-	-	145.80K	372.93K	335.86K
Operating Income	-	-2.07M	-3.55M	-5.57M	-4.75M	-4.92M	-7.17M	-7.79M	-8.37M	-7.65M	-8.43M	-2.75M	-26.31M	-18.97M	-15.22M	-11.56M	-15.65M
Net Income	-1.20M	-2.26M	-4.07M	-6.54M	-5.75M	-5.59M	-7.92M	-8.64M	-9.44M	-12.52M	-14.65M	-11.27M	-44.30M	-18.49M	-10.42M	-8.98M	-14.24M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-5.11	-2.47	-1.16	-1.58
R&D Expense	-	11.62K	12.00K	756.78K	1.59M	1.43M	2.11M	2.88M	2.15M	1.51M	1.72M	876.83K	729.06K	3.51M	4.03M	6.71M	10.09M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	468.51K	220.97K	1.27M	1.38M	1.69M	2.02M	1.58M	1.76M	1.19M	1.47M	4.35M	22.45M	16.43M	12.61M	12.28M	4.08M
Total Equity	0	-51.09K	-744.22K	-3.69M	-5.14M	-6.69M	-6.89M	-3.91M	-5.00M	-6.84M	-8.64M	-12.78M	-1.33M	21.60M	10.29M	10.00M	8.53M	356.74K
Cash & Equivalents	-	-	-	-	-	-	-	-	-	-	-	-	-	21.03M	1.71M	884.38K	547.89K	1.51M
Long Term Debt	-	-	196.88K	-	-	-	-	-	-	-	-	-	-	250.00K	-	-	-	-
Total Liabilities	-	-	1.21M	3.91M	6.41M	8.07M	8.58M	5.93M	6.58M	8.60M	9.83M	14.24M	5.68M	856.50K	602.62K	2.61M	3.75M	-
Current Liabilities	-	-	1.02M	3.91M	2.82M	7.50M	8.52M	5.61M	5.84M	8.35M	9.25M	13.72M	1.04M	363.82K	440.30K	2.61M	3.75M	3.72M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-729.22K	-2.81M	-3.18M	-2.67M	-	-	-	-3.85M	-5.10M	-6.92M	-1.96M	-3.33M	-5.91M	-6.43M	-8.23M	-10.79M
Investing Cash Flow	-48.78K	14.23K	-1.00M	-11.16K	-	-	-	-3.62K	-12.87K	-35.63K	-	-30.66K	-13.40M	3.25M	514.53K	8.90M
Financing Cash Flow	796.03K	2.85M	4.12M	2.88M	-	-	-	4.28M	4.78M	6.84M	5.03M	21.32M	-	2.35M	7.38M	2.85M
Capital Expenditure	-45.38K	-17.77K	-2.53K	-11.16K	-168.38K	-408.07K	-188.76K	-3.62K	-12.87K	-35.63K	-	-30.66K	-265.22K	-171.04K	-106.19K	-116.07K
Free Cash Flow	-774.60K	-2.83M	-3.19M	-2.68M	-	-	-	-3.86M	-5.12M	-6.95M	-	-3.36M	-6.18M	-6.60M	-8.34M	-10.91M
Share Buybacks	28.00K	4.00K	0	0	-	-	-	-	-	-	-	-	-	-	-	0

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	91.6%	87.6%	48.6%	58.4%	99.7%	100.0%	-	-	-	-	-	100.0%	93.0%	93.4%
Operating Margin %	-	-	-	-35,746.1%	-282,873.2%	-1,183.3%	-1,140.1%	-21,414.0%	-10,338.6%	-6,889.8%	-6,486.2%	-3,574.1%	-57,191.0%	-15,838.1%	-10,439.5%	-2,881.6%	-4,350.1%
Net Margin %	-	-	-	-41,931.6%	-342,333.0%	-1,343.2%	-1,259.9%	-23,755.4%	-11,660.1%	-11,277.3%	-11,267.6%	-14,639.9%	-96,311.5%	-15,438.0%	-7,145.2%	-2,239.2%	-3,959.4%
ROE %	2,343.3%	304.2%	110.5%	127.1%	86.0%	81.1%	202.7%	172.7%	138.1%	144.9%	114.7%	846.6%	-205.1%	-179.7%	-104.1%	-105.3%	-3,992.2%
ROCE %	-	378.1%	96.4%	360.0%	77.7%	72.0%	199.4%	182.5%	127.0%	94.9%	68.8%	-83.3%	-119.1%	-118.6%	-152.1%	-135.4%	-4,386.1%

Shareholding Pattern

Insiders

9.56%

Institutions

13.90%

Public Float

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Jane Street Group, LLC	2.91%	40.18K	$108.07K
2	HRT Financial LP	2.57%	35.53K	$95.58K
3	Xtx Topco Ltd	1.04%	14.32K	$38.53K
4	Citadel Advisors Llc	0.99%	13.66K	$36.76K
5	Vanguard Fiduciary Trust Co	0.66%	9.06K	$24.38K
6	Geode Capital Management, LLC	0.55%	7.62K	$20.50K
7	Citigroup Inc.	0.23%	3.19K	$8.57K
8	Wealth Alliance, LLC	0.14%	2.00K	$5.38K
9	State Street Corporation	0.12%	1.62K	$4.37K
10	Keystone Financial Group	0.10%	1.43K	$3.85K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BRTX

Google News Fri, 15 May 2026

What Makes Biorestorative Therapies (BRTX) a New Buy Stock - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNTUlXRktxS3hYRTZ4MU1NbXNPaW5Icy1yOWlZTHdhbjd2YzlxaHVmMU5BT0lCZFkzbk1MOThWODVlWDJkRG1VeVQ4Y04wdkE4NnZiUG5CSHAyNTNtOVBtc25yMEFfZS03MDhraTMwUU9LMXFhenZONDdDbUNTY3l2ZWRRaG0ya1h3ZFFEOX…

Google News Wed, 02 Sep 2026

BioRestorative Therapies Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOSnctbWlieHlUOUJrNDVfMWdJcm0tVi0xcDFzdUl5NjVid2lNY0NUc3VRVkEwSS1yUmhKbU5kTU40clBvUm1RWmNlQVd6TDZidFFsZklISzVzR2dYTGNscmh0N0lnUVVjZmNmc3V2a3pETVJnbVFYejZXdjFqX1BZOHVEZ25ka01pRFlFX1…

Google News ue, 26 May 2026

BRTX - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1zYTAtWi1hbXF2MTZLbE90OUtBNFJkMm1tRi1KZlJQVWpidHBCQUhlWEhubjM0M3NFVHVpUVhvVkFVclJXNFE?oc=5" target="_blank">BRTX</a>  <font color="#6f6f6f">Finviz</font>…

Google News Fri, 14 Aug 2026

BioRestorative Therapies (BRTX) delays Q2 10-Q amid losses and going-concern risk - Stock Titan

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQdFdaR1E2WFllbjFaVUtuTWo1a3FWWUEzTUlNaFZORC1DQTU1dmdFSHJXSVZycERkU3VteHhXQjMtOW9ISmFIM2RnZTFWbjA1cl8tRG02cW9xZ1VGYW5kSXZKVXRPUHl2cTZ6ejcxWTlHRlc4QjlDc084Y3RyN2V1LXJGZkVaNW40Z1pjQ2…

Google News Sat, 05 Sep 2026

NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM - Bitget

<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTFBwbTR2N0JILU1TazRiZm1ET3lpcEZ1aEF6c3Fmcm1qSDBkY0ZxYUlGdHMwOTRSQjNPazhjSmhpT1hDSGVDbGlld0ZnWXdyX0NJazZwd1VpRnFUZFdKQXJGUi1Sc9IBY0FVX3lxTFBwbTR2N0JILU1TazRiZm1ET3lpcEZ1aEF6c3Fmcm1qSD…

Google News hu, 12 Feb 2026

BioRestorative Therapies stock plunges after $5 million public offering - Investing.com

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPaGtrLTl1WWhLLXBBd2phWTFBU0VzWWZxTmlxYlczdVBEUTNQQzNEUGhNRGszT1NTU3dLTUtMQUk3Wm1Ua2JZZDg4cjZrYTVudW1CYTAzeDloUkRTSDFCcmZCWUdnLWc1Vm5XY2RudDNGUEFkcjV3SjhrZWFyUlk4V2pNaDdlQU1uZzR0bT…

BRTX — Frequently Asked Questions

What is the current share price of BioRestorative Therapies, Inc. (BRTX)?

As of 2026-09-19 21:16 PDT, BioRestorative Therapies, Inc. (BRTX) trades at $2.80 on NasdaqCM. Its 52-week range is $0.14 to $2.96.

What is the market capitalisation of BRTX?

BioRestorative Therapies, Inc. (BRTX) has a market capitalisation of $3.87M on NasdaqCM.

What is the P/E ratio of BRTX?

BRTX trades at a trailing price-to-earnings (P/E) ratio of -0.13. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.15.

Is BRTX a good stock to buy?

This page provides a data-driven analysis of BioRestorative Therapies, Inc. (BRTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

BioRestorative Therapies, Inc. BRTX PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

What Makes Biorestorative Therapies (BRTX) a New Buy Stock - finance.yahoo.com

BioRestorative Therapies Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance - Quiver Quantitative

BRTX - Finviz

BioRestorative Therapies (BRTX) delays Q2 10-Q amid losses and going-concern risk - Stock Titan

NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM - Bitget

BioRestorative Therapies stock plunges after $5 million public offering - Investing.com

BRTX — Frequently Asked Questions

What is the current share price of BioRestorative Therapies, Inc. (BRTX)?

What is the market capitalisation of BRTX?

What is the P/E ratio of BRTX?

Is BRTX a good stock to buy?

Explore More